

**Figure S1. (A,B)** Dot plots obtained by flow cytometry analysis after incubation of fluorescent recombinant (A) or commercial antibody (B) with different numbers of WKZ-1 and BL21. **(C,D)** Dot plots obtained by flow cytometry analysis after incubation of fluorescent recombinant (C) or commercial (D) antibody with different numbers of WKZ-2 and BL21.



(B) ATCC 27853 + Recombinant antibody BL21



(C) ATCC BAA-2108 + Recombinant antibody



**Figure S2.** Dot plots obtained by flow cytometry analysis after incubating fluorescent recombinant antibody with different numbers of UCBPP PA14 (A), ATCC 27853 (B), or ATCC BAA-2108 (C).











**Figure S3.** Dot plots obtained by flow cytometry analysis after incubating fluorescent commercial antibody with different numbers of UCBPP PA14 (A), ATCC 27853 (B), or ATCC BAA-2108 (C).



Figure S4. ELISA signals of recombinant scFv against UCBPP PA14 (A), ATCC 27853(B), or ATCC BAA-2108 (C).



**Figure S5.** Dot plots obtained by flow cytometry analysis after incubating fluorescent recombinant scFv with different numbers of UCBPP PA14 (A), ATCC 27853 (B), or ATCC BAA-2108 (C).

## (A) UCBPP PA14 + Recombinant scFv



**Figure S6. (A,B)** Overlaying histograms obtained by flow cytometry analysis after incubation of fluorescent 6DW2 with different numbers of WKZ-2-included commercially available apple juice. Mock pathogenic apple juice sample was centrifuged and fluorescent dye-labeled 6DW2 was added to the pellet (A). Fluorescent 6DW2 was added to mock pathogenic apple juice, and the sample was centrifuged (B). (C,D) Positive signal ratio of the mean of fluorescence intensity of range-gated in each histogram. Error bars represent ±1 SD (n = 3). (E,F) Dot plots obtained by flow cytometry.